Analysis reveals STC2's role in calcium regulation in osteosarcoma, suggesting potential as a biomarker and therapy target.
Our findings suggest that calcium homeostasis dysregulation is involved in OS progression and that STC2 is a prioritized prognostic and functional candidate within this network. The findings suggest that STC2 may serve as a potential therapeutic target and candidate biomarker for OS, including in the context of predicted immunotherapy response, although this requires further validation.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: